MCM
AXDX

Mazama Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Mazama Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-119
Closed -$26K – 17
2015
Q4 		$26K Hold
119
– – ﹤0.01% 243
2015
Q3 		$19K Sell
119
-2,581
-96% -$558K ﹤0.01% 250
2015
Q2 		$697K Sell
2,700
-385
-12% -$91.9K 0.14% 153
2015
Q1 		$694K Buy
+3,085
New +$645K 0.14% 162
2014
Q2 		– Sell
-249
Closed -$54K – 273
2014
Q1 		$54K Sell
249
-85
-25% -$12.6K 0.05% 134
2013
Q4 		$41K Buy
+334
New +$44.6K 0.02% 189

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Mazama Capital Management's AXDX Position: Q1 2016 in Review

Mazama Capital Management sold out of Accelerate Diagnostics (AXDX) in Q1 2016, closing a stake of 119 shares — an estimated $26K sold.

Mazama Capital Management first reported a position in AXDX in Q4 2013 and held it in 6 quarters. The position peaked at $697K in Q2 2015. 92 funds tracked by Wall St. Rank hold AXDX as of Q1 2016.

  • Mazama Capital Management reported no remaining Accelerate Diagnostics position as of Q1 2016 after selling out during the quarter.
  • Mazama Capital Management sold 119 Accelerate Diagnostics shares in Q1 2016, an estimated $26K.
  • Mazama Capital Management first reported a position in Accelerate Diagnostics in Q4 2013 and held it in 6 quarters.
  • Mazama Capital Management's Accelerate Diagnostics position peaked at $697K in Q2 2015.
  • 92 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2016.

Based on Mazama Capital Management's 13F filing for Q1 2016.